113 related articles for article (PubMed ID: 26711145)
1. Structure-based design, synthesis, and biological evaluation of Leu-Arg dipeptide analogs as novel hepsin inhibitors.
Kwon H; Kim Y; Park K; Choi SA; Son SH; Byun Y
Bioorg Med Chem Lett; 2016 Jan; 26(2):310-314. PubMed ID: 26711145
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteres.
Kwon H; Ha H; Jeon H; Jang J; Son SH; Lee K; Park SK; Byun Y
Bioorg Chem; 2021 Feb; 107():104521. PubMed ID: 33334587
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances of Hepsin-Targeted Inhibitors.
Kwon H; Han J; Lee KY; Son SH; Byun Y
Curr Med Chem; 2017; 24(21):2294-2311. PubMed ID: 28245763
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of dye-conjugated hepsin inhibitors.
Kim K; Kwon H; Choi D; Lim T; Minn I; Son SH; Byun Y
Bioorg Chem; 2019 Aug; 89():102990. PubMed ID: 31136899
[TBL] [Abstract][Full Text] [Related]
5. α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.
Han Z; Harris PK; Karmakar P; Kim T; Owusu BY; Wildman SA; Klampfer L; Janetka JW
ChemMedChem; 2016 Mar; 11(6):585-99. PubMed ID: 26889658
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and activity of pyrrolidinyl- and thiazolidinyl-dipeptide derivatives as inhibitors of the Tc80 prolyl oligopeptidase from Trypanosoma cruzi.
Joyeau R; Maoulida C; Guillet C; Frappier F; Teixeira AR; Schrével J; Santana J; Grellier P
Eur J Med Chem; 2000 Feb; 35(2):257-66. PubMed ID: 10758287
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology.
Damalanka VC; Han Z; Karmakar P; O'Donoghue AJ; La Greca F; Kim T; Pant SM; Helander J; Klefström J; Craik CS; Janetka JW
J Med Chem; 2019 Jan; 62(2):480-490. PubMed ID: 30571119
[TBL] [Abstract][Full Text] [Related]
8. Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.
Goswami R; Wohlfahrt G; Törmäkangas O; Moilanen A; Lakshminarasimhan A; Nagaraj J; Arumugam KN; Mukherjee S; Chacko AR; Krishnamurthy NR; Jaleel M; Palakurthy RK; Samiulla DS; Ramachandra M
Bioorg Med Chem Lett; 2015 Nov; 25(22):5309-14. PubMed ID: 26421993
[TBL] [Abstract][Full Text] [Related]
9. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
Xuan JA; Schneider D; Toy P; Lin R; Newton A; Zhu Y; Finster S; Vogel D; Mintzer B; Dinter H; Light D; Parry R; Polokoff M; Whitlow M; Wu Q; Parry G
Cancer Res; 2006 Apr; 66(7):3611-9. PubMed ID: 16585186
[TBL] [Abstract][Full Text] [Related]
10. Potent, small-molecule inhibitors of human mast cell tryptase. Antiasthmatic action of a dipeptide-based transition-state analogue containing a benzothiazole ketone.
Costanzo MJ; Yabut SC; Almond HR; Andrade-Gordon P; Corcoran TW; De Garavilla L; Kauffman JA; Abraham WM; Recacha R; Chattopadhyay D; Maryanoff BE
J Med Chem; 2003 Aug; 46(18):3865-76. PubMed ID: 12930148
[TBL] [Abstract][Full Text] [Related]
11. Allosteric antibody inhibition of human hepsin protease.
Koschubs T; Dengl S; Dürr H; Kaluza K; Georges G; Hartl C; Jennewein S; Lanzendörfer M; Auer J; Stern A; Huang KS; Packman K; Gubler U; Kostrewa D; Ries S; Hansen S; Kohnert U; Cramer P; Mundigl O
Biochem J; 2012 Mar; 442(3):483-94. PubMed ID: 22132769
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.
Herter S; Piper DE; Aaron W; Gabriele T; Cutler G; Cao P; Bhatt AS; Choe Y; Craik CS; Walker N; Meininger D; Hoey T; Austin RJ
Biochem J; 2005 Aug; 390(Pt 1):125-36. PubMed ID: 15839837
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of small-molecule inhibitors of hepsin.
Chevillet JR; Park GJ; Bedalov A; Simon JA; Vasioukhin VI
Mol Cancer Ther; 2008 Oct; 7(10):3343-51. PubMed ID: 18852137
[TBL] [Abstract][Full Text] [Related]
14. Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2.
Damalanka VC; Janetka JW
Future Med Chem; 2019 Apr; 11(7):743-769. PubMed ID: 30945556
[TBL] [Abstract][Full Text] [Related]
15. Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
Franco FM; Jones DE; Harris PK; Han Z; Wildman SA; Jarvis CM; Janetka JW
Bioorg Med Chem; 2015 May; 23(10):2328-43. PubMed ID: 25882520
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of prolyl oligopeptidase with a synthetic unnatural dipeptide.
Racys DT; Rea D; Fülöp V; Wills M
Bioorg Med Chem; 2010 Jul; 18(13):4775-82. PubMed ID: 20627594
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.
Subedi M; Minn I; Chen J; Kim Y; Ok K; Jung YW; Pomper MG; Byun Y
Eur J Med Chem; 2016 Aug; 118():208-218. PubMed ID: 27128184
[TBL] [Abstract][Full Text] [Related]
18. Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.
Tang X; Mahajan SS; Nguyen LT; Béliveau F; Leduc R; Simon JA; Vasioukhin V
Oncotarget; 2014 Mar; 5(5):1352-62. PubMed ID: 24657880
[TBL] [Abstract][Full Text] [Related]
19. Solid-phase synthesis of benzisothiazolones as serine protease inhibitors.
Yu KL; Civiello R; Roberts DG; Seiler SM; Meanwell NA
Bioorg Med Chem Lett; 1999 Mar; 9(5):663-6. PubMed ID: 10201825
[TBL] [Abstract][Full Text] [Related]
20. Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis.
Li W; Wang BE; Moran P; Lipari T; Ganesan R; Corpuz R; Ludlam MJ; Gogineni A; Koeppen H; Bunting S; Gao WQ; Kirchhofer D
Cancer Res; 2009 Nov; 69(21):8395-402. PubMed ID: 19843851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
